Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15895045 | 0.94 | TSHR (0.39) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL14413619 | 0.90 | TSHR (0.39) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL18611903 | 0.86 | LPAR6 (0.36) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL16358125 | 0.86 | USP2 (0.39) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL17792592 | 0.83 | TSHR (0.44) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL16638481 | 0.81 | USP2 (0.46) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL17176225 | 0.80 | MGAM (0.32) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL6229989 | 0.79 | TSHR (0.41) | TSHRALDH1A1CNR2CNR1MGAM | |
| SCHEMBL15721387 | 0.79 | USP2 (0.45) | TSHRMGAMUSP2 | |
| SCHEMBL17145896 | 0.79 | USP2 (0.45) | TSHRMGAMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | TSHR 999/4885ALDH1A1 106/4885CNR2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.